What is everyone's assessment of pyrilutamide 1.0% topical as a adjunct treatment? 6/16/2026
The conversation discusses the use of pyrilutamide as an adjunct treatment for hair loss, particularly for those already using finasteride and minoxidil. Users share mixed experiences, with some reporting side effects like numbness and gynecomastia, while others note its potential benefits in reducing shedding and scalp itchiness.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity How many guys on here are doing the low dose topical finasteride (solo without minox)?
User discusses using low dose topical finasteride without minoxidil for hair loss. Another user shares their experience with homemade 0.025% finasteride topical, shedding, and microneedling.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community My hair became curly after 9 months on fin + min. How common is this?
Hair texture changes, such as hair becoming curly, are common when using treatments like finasteride and minoxidil. Users report various experiences with these treatments, including changes in hair density and texture, with some using additional products like alfatrodial, fluridil, and pyrilutamide for hair maintenance.
community Rate my treatment stack from 1-10
The conversation discusses various hair loss treatments, with a focus on pyrilutamide, minoxidil, and alternatives to finasteride due to intolerance. Users suggest adding a DHT blocker like finasteride or dutasteride, and some recommend trying topical versions to reduce side effects.
community 33M, Skullet guy here, 3 months on 1mg Finasteride, 2 months on 5% Minoxidil, and about a month and a half of derma rolling.
A 33-year-old man is experiencing positive hair regrowth after 3 months on 1mg finasteride, 2 months on 5% minoxidil, and 1.5 months of derma rolling. He is hopeful for further progress and considering additional treatments like dutasteride and microneedling.
Related Research
6 / 6 resultsresearch Androgenetic Alopecia: Therapy Update
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
research Topical solutions for androgenetic alopecia: evaluating efficacy and safety
This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.
research The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Pathophysiology of Androgenetic Alopecia and Implications for Treatment: An Overview of Current Literature
Androgenetic alopecia treatments focus on reducing hair loss by targeting hormones, with new therapies showing promise but needing more research.
research Updates in Treatment for Androgenetic Alopecia
This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.